Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory

January 20, 2021

Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany.

The Clinical Laboratory Science (CLS) team in Marburg, consisting of approximately 80 scientists and analysts, will be transferred to Nexelis. The CLS team in Marburg will continue to keep a strong relationship with GSK and support the development of future GSK vaccine candidates through a 5-year agreement.

The transaction with GSK will be effective at the end of January 2021. Nexelis intends to expand the Marburg site, initiating collaborations with other vaccine development companies as well as with the company’s other North American and European sites.

For more information, click here.